CD19 and neoplasm: Hunter et al. reported that CD8-targeted LNPs could be used to successfully deliver anti-CD19 CAR mRNA and generate CAR T cells in vivo, resulting in tumor control in humanized mice and B cell depletion in cynomolgus monkeys [308].